ARQT
Arcutis Biotherapeutics, Inc.
-1.34 (-5.13%)24.80USD1.9M成交股數3.1B市值112.7本益比(近四季)6.7股價營收比+59.3%營收年增(近四季)2026-10-27下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 130M+97% | 105M+48% | 99.2M+122% | 81.5M+164% | 65.8M+33% | 71.4M+87% | 44.8M+762% | 30.9M+1010% | 49.6M | 38.1M | 5.2M | 2.8M |
| 營業成本 | 10.9M | 9.8M | 8.7M | 7.5M | 8.8M | 6.9M | 5.5M | 3.5M | 3.3M | 1.2M | 776K | 783K |
| 毛利 | 119M+109% | 95.6M+48% | 90.5M+131% | 74.0M+170% | 57.0M+23% | 64.5M+75% | 39.3M+789% | 27.4M+1271% | 46.3M | 36.9M | 4.4M | 2.0M |
| 毛利率 | 91.6% | 90.7% | 91.2% | 90.8% | 86.6% | 90.3% | 87.7% | 88.8% | 93.4% | 96.9% | 85.0% | 71.8% |
| 研發費用 | 20.4M | 30.6M | 19.6M | 19.5M | 17.5M | 14.5M | 19.5M | 19.3M | 23.1M | 26.2M | 25.2M | 35.3M |
| 銷售管理費用 | 82.1M | 74.1M | 62.4M | 69.2M | 64.0M | 57.6M | 58.8M | 58.2M | 54.8M | 47.6M | 46.0M | 42.9M |
| 營業利益 | 16.4M-167% | −9.1M+19% | 8.5M-122% | −14.6M-71% | −24.5M-22% | −7.6M-79% | −39.1M-41% | −50.1M-34% | −31.6M | −36.9M | −66.8M | −76.3M |
| 營業利益率 | 12.7% | -8.6% | 8.6% | -17.9% | -37.3% | -10.7% | -87.3% | -162.3% | -63.8% | -96.8% | -1,286.4% | -2,742.4% |
| 稅後淨利 | 15.0M-160% | −11.3M+5% | 7.4M-118% | −15.9M-70% | −25.1M-29% | −10.8M-76% | −41.5M-41% | −52.3M-35% | −35.4M | −44.8M | −71.0M | −80.1M |
| 淨利率 | 11.6% | -10.7% | 7.5% | -19.5% | -38.1% | -15.1% | -92.8% | -169.6% | -71.4% | -117.5% | -1,367.8% | -2,880.3% |
| 稀釋 EPS | 0.11-155% | -0.090% | 0.06-118% | -0.13-69% | -0.20-38% | -0.09-88% | -0.33-72% | -0.42-68% | -0.32 | -0.73 | -1.16 | -1.31 |
| 稀釋股數 | 136M | 129K | 133M | 127M | 126K | 121M | 124M | 123M | 111M | 61.7M | 61.4M | 61.2M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 34.1M | 34.8M | 47.1M | 72.7M | 53.1M | 71.3M | 135M | 84.3M | 190M | 107M | 105M | 81.4M |
| 應收帳款 | 155M | 144M | 115M | 107M | 85.4M | 73.1M | 60.1M | 43.4M | 37.2M | 19.4M | 17.2M | 12.8M |
| 存貨 | 38.9M | 37.4M | 22.4M | 16.3M | 16.6M | 14.5M | 14.0M | 13.9M | 13.2M | 13.9M | 10.5M | 8.6M |
| 總資產 | 489M | 460M | 371M | 352M | 344M | 349M | 437M | 445M | 479M | 293M | 321M | 379M |
| 有息負債 | 102M | 101M | 107M | 107M | 108M | 107M | 105M | 204M | 203M | 201M | 200M | 199M |
| 總負債 | 268M | 270M | 213M | 213M | 201M | 191M | 281M | 258M | 254M | 246M | 240M | 240M |
| 股東權益 | 221M | 190M | 158M | 139M | 143M | 158M | 157M | 186M | 225M | 46.7M | 80.5M | 140M |
| 負債比 | 54.8% | 58.8% | 57.4% | 60.6% | 58.5% | 54.8% | 64.2% | 58.1% | 53.0% | 84.1% | 74.9% | 63.2% |
| 淨現金(現金 − 有息負債) | −67.8M | −66.7M | −60.4M | −34.3M | −54.5M | −35.9M | 29.8M | −120M | −12.7M | −93.3M | −94.7M | −117M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 2.2M | – | – | −30.4M-4% | – | – | – | −31.6M | – | – | −80.3M |
| 資本支出 | – | 0.00 | – | – | 608K | – | – | – | 0.00 | – | – | 82K |
| 自由現金流 | – | 2.2M | – | – | −31.0M-2% | – | – | – | −31.6M | – | – | −80.4M |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 2.1% | – | – | -47.1% | – | – | – | -63.8% | – | – | -2,892.0% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 376M
| Reportable | 376M | 100.0% | +91.3% |
|---|
產品／服務2025 年度 · 372M
| ZORYVE Foam | 182M | 48.9% | +154.3% |
|---|---|---|---|
| ZORYVE Cream0.3 | 121M | 32.5% | +42.2% |
| ZORYVE Cream0.15 | 68.3M | 18.3% | +588.2% |
| ZORYVE Cream0.05 | 911K | 0.2% | – |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 376M | +91.3% | −16.1M | -4.3% | -0.13 | −6.3M |
| FY2024 | 197M | +229.7% | −140M | -71.3% | -1.16 | −112M |
| FY2023 | 59.6M | +1517.1% | −262M | -439.8% | -3.78 | −247M |
| FY2022 | 3.7M | – | −311M | -8,449.8% | -5.66 | −258M |
| FY2021 | 0.00 | – | −206M | –% | -4.18 | −176M |
| FY2020 | 0.00 | – | −136M | –% | -3.80 | −113M |
| FY2019 | – | – | −42.0M | –% | -22.78 | −43.1M |
| FY2018 | – | – | −19.3M | –% | -15.53 | −14.1M |